Successful treatment of advanced malignant fibrous histiocytoma of the right forearm with apatinib: a case report

Ji, Guangyong; Liu, Hong; Yang, Ping

doi:10.2147/ott.s96133

Cited by 28 publications

(22 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 78-y-old patient with metastatic fibrous histiocytoma received apatinib, and a PR was achieved. 6 The tumor did not progress 6 months after treatment. A 68-y-old patient who was diagnosed with advanced multiple intra-abdominal and pelvic round cell liposarcoma with liver metastasis also got a PR following apatinib administration.…”

Section: Discussionmentioning

confidence: 93%

“…Promising efficacy of apatinib was reported in several subtypes of sarcomas. [6][7][8][9][10] We further retrospectively investigated the outcomes of apatinib in 31 patients with advanced metastatic or recurrent sarcoma who pretreated with at least one chemotherapy regimen or refused to receive chemotherapy. in 7 patients (22.6%) and trunk in 3 patients (9.7%).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study

Zhu

Xie

et al. 2018

Cancer Biology & Therapy

View full text Add to dashboard Cite

Sarcomas are rare but malignant tumors with high risks of local recurrence and distant metastasis. Anti-angiogenic therapy is a potential strategy against un-controlled and not-organized tumor angiogenesis. We aimed to assess the safety and efficacy of apatinib, an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, in patients with advanced sarcoma. Thirty-one patients who received initial apatinib between September 2015 and August 2016 were retrospectively reviewed. Among them, 19 (61.3%) patients were heavily pretreated with two or more lines of cytotoxic chemotherapy. Apatinib was given at a start-dose of 425 mg qd. During therapy, 9 (29.0%) patients required dose interruption and 7 (22.6%) needed dose reduction, and the mean dosage of apatinib was 372.9 ± 68.4 mg/day. In the study cohort, one patient was treated as adjunctive therapy and 6 patients stopped treatment before radiographic response assessment. Thus, 24 patients were eligible for tumor response evaluation. The objective response rate was 33.3% and clinical benefit rate was as high as 75.0%. The progression free survival was 4.25 (95% confidence interval [CI], 2.22-5.11) months, whereas the overall survival was 9.43 (95% CI, 6.64-18.72) months. Compared with other histological subtypes, leiomyosarcoma did not show significant survival benefits. Most of the adverse events (AEs) were at grade 1 or 2. The main grade 3 AEs were hypertension (6.5%), hand foot skin reaction (6.5%), and diarrhea (3.2%). In conclusion, apatinib showed promising efficacy and acceptable safety profile in metastatic or recurrent sarcoma, giving rationale clinical evidence to conduct clinical trials.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study

Zhu

Xie

et al. 2018

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…With a favorable side-effect profile and improved outcomes, apatinib has been shown to be a new therapeutic option in a variety of tumor types. 4 , 9 However, successful use of apatinib in angiosarcomas has not been reported.…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of angiosarcoma of the scalp with apatinib: a case report

Ji¹,

Liu²,

Yang

2016

OTT

Self Cite

View full text Add to dashboard Cite

Angiosarcoma is a rare and aggressive vascular malignancy with a poor prognosis. There is no standard chemotherapy regime for advanced angiosarcoma. Here, we report a case of advanced angiosarcoma that was successfully treated with apatinib, an oral tyrosine kinase inhibitor targeting the intracellular domain of vascular endothelial growth factor receptor-2 (VEGFR-2). To our knowledge, this is the first case to report the successful use of apatinib for angiosarcoma. Furthermore, the administration of apatinib results in fewer toxic effects than traditional cytotoxic chemotherapy. Quantitative polymerase chain reaction analysis revealed high expression of VEGFR-2 mRNA, suggesting that apatinib leads to clinical response by inhibiting VEGFR-2 tyrosine kinase activity and that VEGFR-2 plays a crucial role for angiosarcoma. Apatinib may be an additional option for angiosarcoma especially for the aged and patients with poor performance status. Further prospective studies are required to optimize the use of apatinib in patients with angiosarcoma and to identify which patients will benefit from the agent.

show abstract

“…Its application is being extended for treating non-small-cell lung, breast, and hepatocellular cancers in phase II and III clinical trials across the People's Republic of China. Some case reports have also shown that apatinib has antitumor efficacy against soft tissue sarcoma [ 14 – 16 ]. It is worth noting that anti-angiogenic therapies may work synergistically with conventional chemotherapy treatments [ 17 – 19 ].…”

Section: Introductionmentioning

confidence: 99%

Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma

et al. 2017

View full text Add to dashboard Cite

Angiogenesis is initiated by the activation of the vascular epidermal growth factor receptor-2 (VEGFR-2) by the vascular epidermal growth factor (VEGF) ligand. Overexpression of VEGFR-2 increases the growth of nasopharyngeal carcinomas (NPC). Apatinib (YN968D1) is a highly-selective inhibitor of VEGFR-2, but its effects on NPC have not been hitherto investigated. In the present study, CNE-2 NPC cells were xenografted into 132 nude mice, which were treated with one of 6 drug regimens of apatinib administered alone or in combination with cisplatin (DDP). The impact of treatment regimens on the growth, microvascularization, apoptosis, and metabolic response of tumors, as well as mouse survival was determined by histopathology, immunohistochemistry (VEGFR-2 and CD31), terminal deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL), micro 18F-FDG PET/CT imaging and survival curves. Administration of apatinib alone inhibited tumor growth, reduced microvascular density, and facilitated the apoptosis of tumors. Tumors treated simultaneously with apatinib and cisplatin exhibited significantly-increased inhibition of tumor growth, prolonged survival time, decreased expression of VEGFR-2, reduced microvascular density, and frequency of apoptosis over standalone and sequential administration therapy. Tumors treated simultaneously with apatinib and cisplatin had the lowest uptake of FDG. Taken together, the simultaneous administration of apatinib and cisplatin improves the therapeutic efficacy over standalone treatments, which also led to improved efficacy over sequential administration regimens. VEGFR-2 is an important predictive marker for efficacy of apatinib treatment of NPC.

show abstract

Successful treatment of advanced malignant fibrous histiocytoma of the right forearm with apatinib: a case report

Cited by 28 publications

References 25 publications

Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study

Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study

Successful treatment of angiosarcoma of the scalp with apatinib: a case report

Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma

Contact Info

Product

Resources

About